[HTML][HTML] Greater efficacy of chemotherapy plus bevacizumab compared to chemo-and targeted therapy alone on non-small cell lung cancer patients with brain …
N Tang, J Guo, Q Zhang, Y Wang, Z Wang - Oncotarget, 2016 - ncbi.nlm.nih.gov
Control of non-small-cell lung cancer (NSCLC) with brain metastasis is clinically
challenging. This study retrospectively evaluated the efficacy of different adjuvant therapies …
challenging. This study retrospectively evaluated the efficacy of different adjuvant therapies …
[HTML][HTML] The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis
TH Chiu, PH Tung, CH Huang, JS Ju, ACC Huang… - Scientific Reports, 2022 - nature.com
Abstract Comparison of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-
TKI) monotherapy or with bevacizumab in real-world non-small cell lung cancer (NSCLC) …
TKI) monotherapy or with bevacizumab in real-world non-small cell lung cancer (NSCLC) …
[HTML][HTML] EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases
T Jiang, Y Zhang, X Li, C Zhao, X Chen, C Su… - European Journal of …, 2019 - Elsevier
Introduction Previous studies suggested that epidermal growth factor receptor (EGFR)–
tyrosine kinase inhibitor (TKIs) plus bevacizumab could significantly prolong progression …
tyrosine kinase inhibitor (TKIs) plus bevacizumab could significantly prolong progression …
The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases
Y Fujita, M Kinoshita, T Ozaki, K Takano… - Neuro-Oncology …, 2020 - academic.oup.com
Background Molecular and genetic alterations of non-small-cell lung cancer (NSCLC) now
play a vital role in patient care of this neoplasm. The authors focused on the impact of …
play a vital role in patient care of this neoplasm. The authors focused on the impact of …
Multiple treatment modalities for brain metastasis in patients with EGFR-mutant non-small-cell lung cancer
H Wang, X Yu, Y Fan, Y Jiang - OncoTargets and therapy, 2018 - Taylor & Francis
Background There are many controversies concerning the best management of epidermal
growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients with …
growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients with …
[HTML][HTML] Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010 …
Simple Summary Radiotherapy, in the form of either whole-brain radiotherapy (WBRT) or
stereotactic radiosurgery (SRS), continues as the standard of care for patients of non-small …
stereotactic radiosurgery (SRS), continues as the standard of care for patients of non-small …
[HTML][HTML] Real-world data on prognostic factors for overall survival in EGFR-mutant non-small-cell lung cancer patients with brain metastases
X Yu, Y Fan - Journal of Cancer, 2019 - ncbi.nlm.nih.gov
Background: With the wide application of epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs), the survival of EGFR-mutant non-small-cell lung cancer (NSCLC) …
inhibitors (EGFR-TKIs), the survival of EGFR-mutant non-small-cell lung cancer (NSCLC) …
Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis
Y Lu, Y Fan - OncoTargets and therapy, 2016 - Taylor & Francis
Background Lung cancer is the most common type of cancer to spread to the brain (brain
metastasis [BM]). This study assessed the effect of epidermal growth factor receptor (EGFR) …
metastasis [BM]). This study assessed the effect of epidermal growth factor receptor (EGFR) …
The optimal therapy strategy for epidermal growth factor receptor‐mutated non‐small cell lung cancer patients with brain metastasis: A real‐world study from Taiwan
Background The treatment options for epidermal growth factor receptor (EGFR)‐mutated
non‐small cell lung cancer (NSCLC) with brain metastases (BMs) include EGFR‐tyrosine …
non‐small cell lung cancer (NSCLC) with brain metastases (BMs) include EGFR‐tyrosine …
[HTML][HTML] Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of …
B Zhao, Y Wang, Y Wang, W Chen, L Zhou… - Aging (Albany …, 2020 - ncbi.nlm.nih.gov
Preferable treatments for epidermal growth factor receptor (EGFR)-mutant non-small cell
lung cancer (NSCLC) with brain metastasis are elusive. The study intended to estimate the …
lung cancer (NSCLC) with brain metastasis are elusive. The study intended to estimate the …